Significant findings
Two major conclusions were drawn. First, the beneficial effects of five years of adjuvant tamoxifen are maintained through at least 15 years, in terms of overall survival (P = 0.006), death from breast cancer (P = 0.002), and systemic relapse (P = 0.007). Second, no additional benefit, in survival or freedom from recurrence, was observed in those patients who were randomly assigned to take tamoxifen more than five years.
Comments
This trial confirms the importance of this therapy and the notion that the protective effect of adjuvant tamoxifen is prolonged for many years beyond the completion of treatment. Although a relatively small number of patients received tamoxifen for more than five years, the absence of benefit is in concordance with the findings of the larger National Surgical Breast and Bowel Project trial published in 1996 (see Additional information), and will certainly contribute to the next evaluation of the Oxford meta-analysis. One weakness of this trial is the low percentage of patients with known oestrogen receptor status (57%) and its method of determination.
Methods
Kaplan-Meir (survival curves), two-tailed log-rank test (statistic significance), Cox proportional hazard models (95% confidence intervals)
